Patients treated with drug
STO-REC-STAT01M2KJT2 National
10,000
Global · as of 10 Sep 2026
Patients treated with drug stood at 10,000 as of 10 September 2026 (Roche).
- Publisher
- Roche
- Authority tier
- T2 National
- Locator
- About Enspryng (satralizumab)
- Retrieved
- 15 Sep 2026
- Status
- Verified
What the source says
Enspryng is the first and only IL-6 inhibitor treatment currently approved in approximately 90 countries for neuromyelitis optica spectrum disorder (NMOSD), including in the U.S. and E.U., with a well-established safety profile in over 10,000 patients.
Verbatim extraction verified: The figure 10,000 is directly attested in the quoted passage (About Enspryng (satralizumab)).
The figure above was extracted from this passage. If it does not match, the extraction is wrong and we want to know.
Cite this figure
Published under CC BY 4.0. Attribute the original publisher; the citations below do that for you and link to this permanent record.
- APA
- Roche. (2026). U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments. Retrieved September 15, 2026, from https://www.roche.com/media/releases/med-cor-2026-09-10. Via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA
- MLA
- Roche. "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments." 2026, https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed 15 Sept. 2026 via StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA.
- Chicago
- Roche. "U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments." 2026. https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026. Cited from StatOrigin, https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA.
- BibTeX
- @misc{roche2026patientsbjmgda, author = {{Roche}}, title = {U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments}, year = {2026}, howpublished = {StatOrigin, https://statorigin.org}, url = {https://statorigin.org/stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA}, note = {Original source: https://www.roche.com/media/releases/med-cor-2026-09-10. Accessed September 15, 2026.} }
Provenance and verification
Everything needed to check this number yourself, without taking our word for it.
Chain of Custody · Verification Audit
Primary Source
- Publisher
- Roche · homepage ↗
- Authority tier
- Tier 2 · National Official
- Report
- U.S. FDA grants Priority Review for Roche’s Enspryng for MOGAD, an autoimmune disease with no approved treatments
- Type
- Press release
- Published
- 10 September 2026
- Locator
- About Enspryng (satralizumab)
- Retrieved
- 15 September 2026
- Link status
- Reachable (HTTP 200)
- Report licence
- See source
Verification & Integrity
- Audit status
- Verified
- Review protocol
- Editorial review
- Checked on
- 15 September 2026
- Last revision
- 15 September 2026
- Archival URI
- /stat/stat_01M2KJ7XCG3Y4BJ2059JBJMGDA